| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Not applicable. D-Glyceric acid is an endogenous metabolite, not a drug with a specific protein target. It is an intermediate in the metabolic pathways of the body. Its sodium salt form is used as a reference standard for analytical methods. In the context of disease research, it serves as a biomarker. Elevated levels of D-Glyceric acid in urine are characteristic of specific metabolic disorders.
|
|---|---|
| ln Vitro |
D-Glyceric acid sodium is an endogenous metabolite and is not a pharmacologically active compound in the traditional sense. It is not an enzyme inhibitor or receptor agonist. Its "activity" is limited to its role in the metabolic pathway and its use as an analytical standard. It is used as a research tool for the investigation of metabolic disorders, including primary hyperoxaluria type I and glutaric acidemia type 2.
|
| ln Vivo |
No in vivo data is provided for D-Glyceric acid sodium itself, as it is not an administered drug. In the context of the diseases it is used to study, the levels of D-Glyceric acid in the body are altered. For example, in patients with glutaric acidemia type II, the body cannot properly break down proteins and fats, leading to the accumulation of D-Glyceric acid in the urine.
|
| Enzyme Assay |
Not applicable. D-Glyceric acid sodium is a biochemical reagent and analytical standard, not a drug candidate. As a standard, it is used to calibrate instruments and validate methods for metabolomics analysis. A typical protocol involves dissolving the sodium salt in water or methanol to create calibration standards of known concentrations (e.g., 0.5, 1, 5, 10, 50, 100 uM). These are then analyzed by LC-MS/MS to generate a standard curve.
|
| Cell Assay |
Not applicable. D-Glyceric acid sodium is not a drug and is not used in cell-based assays as a pharmacological agent. It may be added to the culture medium of hepatocytes or fibroblasts derived from patients with metabolic disorders to study the metabolic flux through the relevant pathways, but it is not used as a therapeutic or to stimulate a response.
|
| Animal Protocol |
Not applicable. D-Glyceric acid sodium is not administered to animals in a drug-like fashion. For research purposes, it may be spiked into serum or urine samples from animal models of primary hyperoxaluria type I or glutaric acidemia type II to serve as a quality control standard for the quantification of the metabolite by an analytical method.
|
| ADME/Pharmacokinetics |
Not applicable. D-Glyceric acid sodium is an endogenous metabolite and an analytical standard. It is not a xenobiotic drug, and its pharmacokinetics are not studied. D-Glyceric acid is produced and metabolized in the body, and its concentration in biofluids is a function of the balance between production and clearance.
|
| Toxicity/Toxicokinetics |
Not applicable. D-Glyceric acid is an endogenous, naturally occurring compound. Its sodium salt is a biochemical that is considered safe to handle under standard laboratory conditions. There is no toxicological concern for this compound when used as an analytical reagent.
|
| References |
|
| Additional Infomation |
D-Glyceric acid sodium is a research-grade biochemical and analytical standard. Its CAS number is 109175-64-6, molecular formula is C3H₅NaO4, and molecular weight is 128.06. It is supplied with high purity (typically ≥99%). The compound is intended for laboratory research only and is not for human consumption. It is soluble in water and should be stored at 4degC. Each product in one row, fields tab-separated.
|
| Molecular Formula |
C3H5NAO4
|
|---|---|
| Molecular Weight |
128.06
|
| Exact Mass |
128.009
|
| CAS # |
109175-64-6
|
| Related CAS # |
D-Glyceric acid calcium hydrate; D-Glyceric acid; 6000-40-4
|
| PubChem CID |
155487365
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
8
|
| Complexity |
73.7
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C([C@H](C(=O)[O-])O)O.[Na+]
|
| InChi Key |
IUEMQUIQAPPJDL-HSHFZTNMSA-M
|
| InChi Code |
InChI=1S/C3H6O4.Na/c4-1-2(5)3(6)7;/h2,4-5H,1H2,(H,6,7);/q;+1/p-1/t2-;/m1./s1
|
| Chemical Name |
sodium (2R)-2,3-dihydroxypropanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 50 mg/mL (~390.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.8088 mL | 39.0442 mL | 78.0884 mL | |
| 5 mM | 1.5618 mL | 7.8088 mL | 15.6177 mL | |
| 10 mM | 0.7809 mL | 3.9044 mL | 7.8088 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
